Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy
2019-003563-22Phase 3Terminated
- Sponsor
- Astria Therapeutics
- Start
- Jan 2020
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edasalonexent in Duchenne muscular dystrophy (DMD), sponsored by Astria Therapeutics. Primary endpoint: Safety and tolerability. Started Jan 2020; status: terminated.
02
Drugs
edasalonexent
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2019-003563-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003563-22.